Novel bronchodilators in the treatment of asthma and COPD

Bibliography

• SIAFAKAS NM, VERMEIRE P, PRICE NB: Optimal assessment and management of chronic obstructive pulmonary disease (COPD): The European Respiratory Society Task Force. Eur. Respic J. (1995) 8:1398–1420.
   PubMed Web of Science ®Google Scholar
• Standards for the diagnosis and care of patients with chronic obstructive pulmonary disease. American Thoracic Society. Am. j Respic Cam. Med. (1995) 152:S77–S121.
   Google Scholar
• BTS guidelines for the management of chronic obstructive pulmonary disease: The COPD Guideline Group of the Standards of Care Committee of the BTS. Thorax (1997) 52:S1–S28.
   Google Scholar
• •Guideline for management of COPD.
   Google Scholar
• Asthma in children under five years of age. The General Practitioner in Asthma Group, the British Association of Accident and Emergency Medicine, the British Paediatric Respiratory Society and the Royal College of Paediatrics and Child Health. Thorax (1997) 52:S9-10, S18–21.
   Google Scholar
• Asthma in adults and schoolchildren. The General Practioner in Asthma Group, the British Association of and Emergency Medicine, the British Paediatric Respiratory Society and the Royal College of Paediatrics and Child Health. Thorax (1997) 52:S2-8,S11-15,S20–21.
   Google Scholar
• •Guideline for management of asthma.
   Google Scholar
• WEGNER CD: Novel mechanistic targets for the treatment of sub-acute and chronic bronchitis. Curr. Pharm. Design (2001) 7:199–212.
   PubMed Web of Science ®Google Scholar
• WHO Fact Sheet No. 206. Revised January2000.
   Google Scholar
• VIEGI G, PEDRESCHI M, PISTELLI F et al.: Prevalence of airways obstruction in a general population. European Respiratory Society vs. American Thoracic Society Definition. Chest (2000) 117:339S–345S
   Google Scholar
• GARY T: Recommendations for the Management of COPD. Chest (2000) 117:23S–28S
   Google Scholar
• CULPITT S, ROGERS V, DUNCAN F: Evaluation of current pharmacotherapy of chronic obstructive pulmonary disease. Expert Opin. Pharmacother. (2000) 1(5):1007–1020.
   PubMedGoogle Scholar
• MICHAEL R: The reality of drug use in COPD. The European perspective. Chest (2000) 117:29S–32S
   Google Scholar
• DONOHUE JF, OHAR JA: New combination therapies for asthma. Curc Opin. Pulm. Med. (2001) 7(2): 62–68.
   PubMedGoogle Scholar
• GRAUL A, CASTANER J: Treatment of COPD, I32-adrenoceptor agonist, dopamine D2 agonist. Drugs Future (2000) 25(2):165–169.
   Google Scholar
• HANDLEY D: The asthma-like pharmacology and toxicology of (.9-isomers of 13 agonists. j Allergy Chia. Immunol (1999) 104:S69–76.
   Google Scholar
• COSTELLO J: Prospects for improved therapy in chronic obstructive pulmonary disease by the use of levalbuterol. _J. Allergy brimurrol. (1999) 104:S61–68
   Google Scholar
• CULPITT SV, ROGERS DF: Evaluation of current pharmacotherapy of chronic obstructivepulmonary disease. Expert Opin. Pharmacother. (2000) 1(5):1007–1020.
   PubMedGoogle Scholar
• RENNARD SI: Anticholinergic bronchodilators: Historical perspective, basic pharmacology and overview of clinical use. Lung Biol. Health Dis. (2000) 145:159–180.
   Google Scholar
• •An overview of anticholinergic bronchodilators.
   Google Scholar
• PINEDA R, RENNARD SI: Anticholinergics bronchodilator in combination. Expert Opin. Pharmacother. (2000) 1(7):1281–1287.
   PubMedGoogle Scholar
• D'URZO AD, DE SALVO C, RAMIREZ-RIVERA A et al: In patients with COPD, treatment with a combination of formoterol and ipratropium is more effective than a combination of salbutamol and ipratropium: A 3-week, randomized, double-blind, within-patient, multicenter study. Chest (2001) 119:1347–1356.
   PubMed Web of Science ®Google Scholar
• BARNES PJ: The pharmacological properties of Tiotropium. Chest (2000) 117:63S–66S.
   Google Scholar
• CALVERLEY PMA: The future for Tiotropium. Chest (2000) 117:67S–69S
   Google Scholar
• BARNES PJ: Tiotropium bromide. Expert Opin. Investig. Drugs (2001) 10(4): 733–740.
   PubMed Web of Science ®Google Scholar
• THIEN F: Leukotriene antagonists. Do they offer new hope for asthmatics? Aust. Fam. Physician (2000) 29 (6):547–551.
   PubMedGoogle Scholar
• SMITH LJ: Pharmacology and safety of the leukotriene antagonists. Clin. Rev. Allergy Immunol. (1999) 17(1/2):195–212
   Google Scholar
• DEMPSYE OJ: Leukotrinene receptor antagonist therapy. Postgraduate Med. (2000) 76 (902):763–773.
   Google Scholar
• SORKNESS CA: Leukotriene receptor antagonists in the treatment of asthma. Pharmacotherapy (2001) 21(3 Pt 2):34S–37S.
   Google Scholar
• CROWTHER SD, PJ REES: Current treatment of asthma- focus on leukotrienes. Expert Opin. Pharmacother. (2000) 1(5):1021–1040.
   PubMedGoogle Scholar
• KRAWIEC ME, WENZEL SE: Leukotriene inhibitors and non-steroidal therapies in thereatment of asthma. Expert Opin. Pharmacother. (2001) 2(1):47–65.
   PubMedGoogle Scholar
• GARCIA-MARCOS L, SCHUSTER A: Antileukotrienes in asthma: present situation. Expert Opin. Pharmacother. (2001) 2(3):441–466.
   PubMedGoogle Scholar
• •An overview of leukotriene inhibitors for asthma.
   Google Scholar
• GIEMBYCZ MA: Phosphodiesterase 4 inhibitors and the treatment of asthma: where are we now and where do we go from here? Drugs (2000) 59(2):193–212.
   PubMedGoogle Scholar
• SPINA D: The potential of PDE4 inhibitors in asthma or COPD. Curr. Opin. Investig. Drugs (2000) 1(2):204–213.
   PubMedGoogle Scholar
• BARNETTE MS, UNDERWOOD DC: New phosphodiesterase inhibitors as therapeutics for the treatment of chronic lung disease. Curc Opin. Pulm. Med. (2000) 6(2):164–169.
   PubMedGoogle Scholar
• DAL PIAZ V, GIOVANNONI MP: Phosphodiesterase 4 inhibitors, structurally unrelated to rolipram, as promising agents for the treatment of asthma and other pathologies. Eur. j Med. Chem. (2000) 35(5):463–480.
   PubMed Web of Science ®Google Scholar
• XU RX, HASSELL AM, VANDERWALL D et al: Atomic structure of PDE4: insights into phosphodiesterase mechanism and specificity. Science (2000) 288: 1822-1825.
   Google Scholar
• LIU S, LALIBERTE F, BOBECHKO B et al.: Dissecting the cofactor-dependent and independent bindings of PDE4 inhibitors. Biochemistry (2001) 40:10179–10186.
   PubMed Web of Science ®Google Scholar
• LALIBERTE F, HAN Y, GOVINDARAJAN A et al: Conformational difference between PDE4 apoenzyme and holoenzyme. Biochemistry (2000) 39:6449–6458.
   PubMedGoogle Scholar
• HUANG Z, DUCHARME Y, MACDONALD D et al: The next generation of PDE4 inhibitors. Curr. Opin. Chem. Biol. (2001) 5: 432–438.
   PubMed Web of Science ®Google Scholar
• •A review of the recent developments of PDE4 inhibitors for the treatment of asthma and COPD.
   Google Scholar
• GIEMBYCZ MA: Cilomilast: a second generation PDE4 inhibitor for asthma and chronic obstructive pulmonary disease. Expert Opin. Investig. Drugs (2001) 10 (7):1361.
   PubMedGoogle Scholar
• PRASAD MR, BAHEKAR RH, RAO AR: Recent perspectives in the design of antiasthmatic agents. Pharmazie (2000) 55(7):475–482.
   PubMedGoogle Scholar
• TERAO S, SHIRAISHI M, MATSUMOTO T, ASHIDA Y: Thromboxane A2 antagonist, discovery of seratrodast. Yakugaku Zasshi (1999) 119(5):377–390
   PubMed Web of Science ®Google Scholar